Several widely available vitamins have been linked to increased cancer risk in large clinical trials, sometimes dramatically enough to force researchers to halt the studies early. Beta-carotene, vitamin E, and high-dose B vitamins are the best-documented offenders, but the story is more nuanced than a simple blacklist. The risk almost always depends on dose, the form of the supplement, and who is taking it, with smokers and people who already have precancerous changes facing the greatest danger.
Beta-Carotene and Lung Cancer in Smokers
Beta-carotene is the most striking example of a vitamin supplement backfiring. In the 1990s, two large randomized trials tested whether this antioxidant, a precursor to vitamin A found in carrots and leafy greens, could prevent lung cancer in people at high risk. Both trials produced the opposite result.
The ATBC (Alpha-Tocopherol, Beta-Carotene Cancer Prevention) study enrolled tens of thousands of male smokers in Finland. Men who took beta-carotene supplements had a roughly 16% higher risk of developing lung cancer compared with those on placebo. The effect was strongest among heavy smokers: those smoking at least 20 cigarettes a day saw about a 25% increase in lung cancer risk, while lighter smokers showed no significant change. Higher alcohol intake amplified the danger further, with men drinking the equivalent of about one drink a day or more facing a 35% increase in risk.1PubMed. Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance
The CARET (Beta-Carotene and Retinol Efficacy Trial) in the United States confirmed these findings independently. Participants taking a combination of beta-carotene and vitamin A had a 28% higher relative risk of lung cancer and a 17% higher risk of dying from any cause. The risk of death specifically from lung cancer jumped by 46%. The findings were so alarming that the trial was stopped 21 months ahead of schedule.2PubMed. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease
These were not marginal findings from small studies. Both involved thousands of participants followed for years, and the results were consistent across different populations of smokers and former asbestos workers. The mechanism appears to involve the way beta-carotene behaves in the oxidative environment of a smoker’s lungs: instead of neutralizing harmful molecules, it may form breakdown products that actually damage DNA and promote tumor growth. For non-smokers eating beta-carotene-rich foods, there is no comparable alarm. The danger is specific to supplemental doses in people whose lungs are already under oxidative stress.
Vitamin E and Prostate Cancer
Vitamin E was long considered a promising cancer-prevention supplement. An early signal from the ATBC study suggested it might reduce prostate cancer risk, which led to the massive SELECT (Selenium and Vitamin E Cancer Prevention Trial) in the United States. SELECT enrolled more than 35,000 healthy men and randomized them to vitamin E, selenium, both, or placebo.
The results were a disappointment. Men taking vitamin E alone developed prostate cancer at a significantly higher rate than those on placebo, with a 17% increase in risk. In absolute terms, that meant about 1.6 extra cases of prostate cancer per 1,000 men per year of supplementation.3PubMed Central. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
That 17% bump may sound modest, but prostate cancer is extremely common. Applied to the millions of men who were taking vitamin E supplements at the time, even a small increase in relative risk translates into a meaningful number of extra cancers. SELECT effectively ended the era of recommending vitamin E supplements for cancer prevention in healthy men. The finding also reinforced a broader lesson: what works as an antioxidant in a test tube does not always work the same way inside a living human body.
High-Dose B6 and B12
B vitamins are essential nutrients, and most people associate them with energy and nerve health rather than cancer. But the VITAL (Vitamins and Lifestyle) cohort study, which followed more than 77,000 adults for years, found a worrying link between long-term high-dose supplementation and lung cancer in men.
Men who took more than 20 mg per day of vitamin B6 over a 10-year average had close to double the lung cancer risk compared with non-users. The same pattern held for vitamin B12 at doses above 55 micrograms per day, which also nearly doubled the risk. Once again, smoking made things worse: among men who were current smokers at the start of the study, the elevated risk was even higher.4PubMed Central. Long-Term, Supplemental, One-Carbon Metabolism-Related Vitamin B Use in Relation to Lung Cancer Risk in the Vitamins and Lifestyle (VITAL) Cohort
The doses involved here are worth noting. The recommended daily intake of B6 for most adults is under 2 mg, and B12 is measured in micrograms. The supplements flagged by this study contained 10 to 50 times those amounts, which is not unusual for products marketed for “energy” or “stress support.” Women in the study did not show the same elevated risk, which suggests hormonal or metabolic differences may play a role, though the reasons are still being investigated.
Folate’s Double-Edged Biology
Folic acid, the synthetic form of the B vitamin folate, occupies a uniquely conflicted position in cancer research. On one hand, adequate folate intake before and during pregnancy is clearly protective against neural tube defects, and population-level folic acid fortification of grain products has been one of the most successful public health interventions in decades. On the other hand, there is real evidence that folic acid can accelerate the growth of cancers that already exist.
The concern centers on folate’s role in cell division. Folate provides raw materials that cells need to copy their DNA. In healthy tissue, this is a good thing. But precancerous or cancerous cells are dividing rapidly and are hungry for these same materials. Research supports the idea that folic acid is protective when no abnormal cells are present, but may feed existing tumors or precancerous growths.5PubMed Central. The relationship between folic acid and colorectal cancer; a literature review
This dual nature creates a practical dilemma. Colorectal cancer, for example, often develops from polyps that grow silently for years before being detected. A person supplementing with folic acid who happens to have an undetected polyp might inadvertently be feeding that growth. Meanwhile, someone without any precancerous changes might be getting a protective benefit from the same supplement. The timing of exposure relative to the earliest stages of tumor development seems to be what determines whether folate helps or harms.
The folate receptors that shuttle folate into cells are overexpressed in multiple cancers, which is both a clue to why tumors thrive on folate and, ironically, a tool researchers are exploiting for targeted drug delivery.6PubMed Central. Emerging roles for folate receptor FOLR1 in signaling and cancer
How Antioxidants Can Help Tumors Spread
For decades, the public health message around antioxidants was simple: they mop up harmful free radicals, which should protect cells from the kind of damage that leads to cancer. The reality turns out to be far more complicated. Research from the last decade has revealed that, in certain contexts, antioxidants can actually help existing tumors grow and spread.
One key set of experiments showed that supplementation with vitamin E and N-acetylcysteine (a common over-the-counter antioxidant) promoted the spread of lung tumors driven by KRAS mutations, one of the most common oncogenic mutations in human cancers. The antioxidants reduced levels of free heme inside cells and stabilized a protein called BACH1, which then switched on genes that drive metastasis.7PubMed. BACH1 Stabilization by Antioxidants Stimulates Lung Cancer Metastasis
Follow-up work extended this finding beyond metastasis. Researchers found that vitamins C and E, as well as N-acetylcysteine, also increased the formation of new blood vessels that feed tumors, a process called angiogenesis. This happened through the same BACH1 pathway: lower oxidative stress stabilized BACH1, which ramped up genes involved in building new blood supply for the tumor.8JCI Insight. Antioxidants stimulate BACH1-dependent tumor angiogenesis
This does not mean that eating an orange or a handful of almonds is dangerous. The levels of antioxidants involved in these experiments were pharmacological, and the subjects already had established tumors. But the findings explain why the large prevention trials of beta-carotene and vitamin E went wrong. If someone has early, undetected cancer cells, flooding the body with supplemental antioxidants may inadvertently lower the oxidative stress that was helping to keep those cells in check. Free radicals are not purely villains; they are also part of the body’s surveillance system for abnormal cells.
Calcium and Prostate Cancer
Calcium is not technically a vitamin, but it is so commonly bundled with vitamin D in supplements that the two are worth discussing here. Observational data from the Health Professionals Follow-Up Study, which tracked men for 24 years, found that calcium intakes above 2,000 mg per day were associated with a greater risk of total prostate cancer as well as aggressive and lethal forms of the disease.9PubMed Central. Calcium and phosphorus intake and prostate cancer risk: a 24-y follow-up study
Interestingly, those associations weakened and lost statistical significance when researchers accounted for phosphorus intake, suggesting the calcium-to-phosphorus ratio may matter more than raw calcium quantity. Still, a critical review of the literature concluded that high calcium intake, whether from diet or supplements, is associated enough with advanced prostate cancer risk that intervention studies need to evaluate safety more carefully.10PubMed Central. Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review
Most men getting calcium from a normal diet are unlikely to reach the danger zone of 2,000 mg per day. The risk applies mainly to those taking high-dose calcium supplements on top of a calcium-rich diet, particularly older men already concerned about prostate health. The irony is that some of these men take calcium specifically because their doctor recommended it for bone density during hormone therapy for prostate cancer.
What About Multivitamins?
Given that individual vitamins have been linked to specific cancers, a natural question is whether the daily multivitamin most people take carries any overall risk. A pooled analysis of three large U.S. cohorts, covering hundreds of thousands of participants and over 160,000 deaths, found that daily multivitamin users had a slightly higher all-cause mortality risk than non-users. However, the effect was small, with hazard ratios hovering around 1.04, and when researchers looked specifically at cancer mortality, the estimates were close to 1.0 and not clearly significant.11JAMA Network Open. Multivitamin Use and Mortality Risk in 3 Prospective US Cohorts
That tiny elevation in overall mortality is hard to interpret. People who take multivitamins may differ from non-users in ways that are difficult to measure: they might be sicker to begin with, or they might be healthier and more health-conscious, creating confounding in both directions. What the data do make clear is that multivitamins are not providing measurable protection against cancer or death. The old assumption that a daily pill is “insurance” against nutritional gaps does not hold up when you look at hard outcomes.
The Bigger Pattern from Large Reviews
A major Cochrane systematic review pulled together the evidence from dozens of randomized trials testing antioxidant supplements in both healthy people and patients with various diseases. When restricted to the highest-quality trials, the findings were sobering. Beta-carotene increased all-cause mortality by about 5%, and vitamin E increased it by about 3%. Vitamin A trended toward increased mortality as well, with higher doses producing a bigger signal. Vitamin C and selenium showed no significant effect on mortality in either direction.12PubMed Central. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases
These mortality findings are not entirely driven by cancer, as cardiovascular disease contributes too. But the pattern is consistent with the individual trial results: supplemental beta-carotene and vitamin E, at the doses commonly sold over the counter, are associated with a slight but real increase in the chance of dying sooner. The supplements are not inert, and the direction of their effect is the wrong one.
Your Genes May Change the Equation
One of the reasons vitamin-cancer research produces so many seemingly contradictory findings is that people process vitamins differently depending on their genetics. A key example involves a gene called MTHFR, which encodes an enzyme critical to folate processing. Common variants of this gene reduce the enzyme’s activity, altering how the body handles folate and related B vitamins. These variants have been linked to altered cancer risks for several types of malignancy.13PubMed Central. MTHFR C677T and A1298C Polymorphisms in Breast Cancer, Gliomas and Gastric Cancer: A Review
A meta-analysis examining one specific MTHFR variant and colorectal cancer found that people carrying two copies of the variant actually had a modestly lower risk of colorectal cancer compared with those carrying the more common version of the gene. In those same individuals, adequate folate intake appeared to reduce colorectal cancer risk further.14PubMed Central. Meta Analysis of Methylenetetrahydrofolate Reductase (MTHFR) C677T polymorphism and its association with folate and colorectal cancer
This means that a blanket recommendation about folate supplementation and cancer risk is inherently imprecise. Two people taking the same dose of folic acid might experience genuinely different biological effects based on which version of MTHFR they carry. This kind of genetic variability helps explain why some observational studies find folate protective while others find it harmful: the study populations have different genetic makeups, and the results are an average that may not apply well to any individual.
Iron Supplements and Cancer Recurrence
Iron is a mineral rather than a vitamin, but it frequently appears alongside vitamins in supplement formulations and multivitamin pills, making it relevant here. The gut microbiome connection is especially interesting: most bacteria in the colon require iron to grow, and oral iron supplements shift the balance of gut bacteria in ways that may favor cancer-associated species. In colorectal cancer patients, oral iron increased the abundance of bacterial groups enriched in tumors, while intravenous iron did not produce the same shift. Among breast cancer patients, iron supplement use during chemotherapy was associated with a 79% higher risk of disease recurrence.15PubMed Central. Microbiome and diet in colon cancer development and treatment
Iron is essential when you are genuinely deficient, and anemia is a real and serious condition. But the evidence suggests that casual iron supplementation, particularly from oral pills taken without a documented deficiency, may carry risks that are not widely appreciated, especially for people with a history of cancer.
When Vitamins Switch Roles
Vitamin C illustrates how the same molecule can behave completely differently depending on dose and delivery route. At the concentrations you get from food or a typical supplement, vitamin C acts as an antioxidant, donating electrons to neutralize free radicals. But at very high concentrations achievable only through intravenous infusion, vitamin C flips into a pro-oxidant. At pharmacologic doses, it generates hydrogen peroxide selectively within tumor tissue, damaging cancer cells while leaving normal cells largely unharmed.16PubMed Central. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice
This dual behavior is a useful corrective to black-and-white thinking about vitamins and cancer. Vitamin C at dietary levels is not dangerous. Vitamin C at moderate supplement levels is probably neutral. Vitamin C at pharmacologic IV doses is being actively studied as a potential adjunct to cancer treatment. The molecule has not changed; its context has.17PubMed Central. The Result of Vitamin C Treatment of Patients with Cancer: Conditions Influencing the Effectiveness
That same dose-dependent logic applies broadly. The vitamins discussed throughout this article are not poisons. They are essential nutrients that, when consumed in food-level amounts, play critical roles in health. The problems emerge at supplemental doses, especially megadoses taken over years, and especially in people whose biology is already primed for cancer by smoking, genetic variants, or undetected precancerous growths. The distinction between getting your vitamins from food and getting them from a pill is not just about absorption rates or bioavailability. It is about the difference between a finely tuned nutritional signal and a pharmacological sledgehammer.